Table 3. The eligible studies of myopia control interventions on choroidal thickness in pediatric population.
| Author | Study design and quality score | Location | Year | Intervention | Sample size | Age (y)a | Type of OCT | SE (D)a | SFCT(µm)a |
||
| Baseline | The end of treatment | Treatment duration | |||||||||
| Chen[45] | Case-cohort; 7c | China | 2016 | OK | 39 | 10.6±2.5 | RS-3000, NIDEK | -2.90±1.08 | 282±43 | 306±54 | 1mo |
| SVL | 38 | 10.0±2.7 | -2.75±1.08 | 275±60 | 276±64 | ||||||
| Li[46] | Case-cohort; 8c | China | 2019 | OK | 29 | 12.31±1.71 | Spectralis HRA+OCT | -3.16±0.85 | 228±56 | 21.03±12.74 | 12mo |
| SVL | 21 | 11.52±1.69 | -2.98±1.34 | 248±51 | -2.50±14.43 | ||||||
| Jin[47] | Case-cohort; 8c | China | 2018 | OK | 30 | 11.3±1.7 | Cirrus-HD OCT | -2.9±1.1 | 253.1±38.6 | 262.8±44.3 | 3mo |
| Li[48] | Case-cohort; 7c | China | 2020 | 0.01%A | 59 | 9.31±2.43 | SS-OCT, Topcon | -1.39±0.65 | 235.10±30.96 | 255.85±31.71 | 2mo |
| Ye[49] | RCT | China | 2020 | 1%A | 98 | 8.94±1.55 | Topcon Corp. | -2.12±1.09 | 214±45 | 27±23b | 6mo |
| 0.01%A | 87 | 8.84±1.65) | -2.12±1.09 | 218±39 | -5±17b | ||||||
| Zhao[50] | RCT | China | 2021 | 0.01%A | 42 | 9.96±1.03 | Spectralis HRA+OCT | -3.01±1.22 | 251.12±44.76 | 256.61±46.55 | 1mo |
| OK | 36 | 10.33±1.65 | -2.74±1.06 | 266.74±57.50 | 276.17±59.10 | ||||||
| OKA | 39 | 10.23±1.11 | -3.12±1.20 | 263.17±46.55 | 277.28±46.04 | ||||||
| SVL | 37 | 9.73±1.04 | -3.25±1.10 | 258.05±52.34 | 253.24±50.67 | ||||||
| Hao[51] | RCT | China | 2021 | 0.01%A | 22 | 9.77±1.27 | CIRRUS HD-OCT | -3.62±0.57 | 240.64±19.93 | 248.73±21.06 | 12mo |
| OK | 24 | 10.13±1.19 | -3.66±0.60 | 236.83±16.78 | 256.17±19.03 | ||||||
| OKA | 21 | 10.10±1.22 | -4.07±0.74 | 235.14±20.33 | 259.29±21.73 | ||||||
| Xiong[52] | RCT | China | 2021 | OK | 81 | 10.88±1.92 | Carl Zeiss | -3.42±1.28 | 284.36±72.58 | 299.33±73.65 | 6mo |
| LLLT+SVL | 74 | 10.22±2.38 | -3.42±1.28 | 288.61±59.59 | 323.91±65.63 | ||||||
| SVL | 74 | 10.33±2.03 | -3.32±1.36 | 286.81±63.67 | 269.97±64.11 | ||||||
| Kong[53] | RCT | China | 2021 | 0.01%A | 50 | 9.12±1.39 | RS-3000, NIDEK | -2.25±1.14 | 233.45±22.95 | -9.18±19.52b | 6mo |
| AAS+0.01%A | 50 | 8.96±1.38 | -2.14±1.27 | 233.45±22.95 | -7.92±20.65b | ||||||
| Wang[54] | RCT | China | 2022 | 0.01%A | 21 | 9.90±1.58 | Spectralis HRA+OCT | -2.38±1.46 | 249.98±38.26 | 261.10±43.25 | 3mo |
| SVL | 19 | 9.89±1.94 | -2.36±1.87 | 229.78±46.73 | 235.31±46.43 | ||||||
| Xu[55] | RCT | China | 2022 | PPALs | 59 | 9.2±1.1 | Cirrus HD-OCT | -2.38±0.61 | 231.60±51.84 | 202.17±56.78 | 24mo |
| FPALs | 48 | 9.4±1.1 | -2.38±0.61 | 230.46±57.36 | 210.87±68.29 | ||||||
| SVL | 61 | 9.2±1.1 | -2.38±0.61 | 231.65±56.77 | 209.51±64.98 | ||||||
aData was shown in means±SD; bData was shown in change values from final to baseline; cThe Newcastle Ottawa Scale was used for quality assessment in the included studies. RCT: Randomized controlled trial; OCT: Optical coherence tomography; SE: Spherical equivalent; SFCT: Sub-foveal choroidal thickness; A: Atropine; OK: Orthokeratology; OKA: Orthokeratology combined with 0.01% atropine; SVL: Single-vision lens; LLLT: Low-intensity, long-wavelength red light therapy; PPALs: Personalized progressive addition lens; FPALs: Fixed progressive addition lenses; ACS: Auricular acupoint stimulation.